387641 Re +k B Principles of Immunology Zz ® AAR LEP HRERA SAA EH AE ME BE A BE AR DR EH ha thAS # EE AGES LER AR HH RO EAA A LO RES ME AMEZORREER ARAM SOE EMEA. KP OERER BRAM RIS SE 17 A RH ERE RS SEAGATE BLA RADA BR BEY TTI, WL OR BE I A SE TT Hk BE EOE A BAST A A te AR HE A FE FT A AHL 20 Hh RAF —-AARABAS SB, KS EI BE A AEA RR BE PARRHEST AAAS S.ime ReR REA BR ST Pp ABR BORE Dah za Zia REE ee + RA REA BAK (BREE) MES eM (8 RHE UE HEL) LEHI ERAS, LG HRRE AA, AA OEE BE EGHO BRAD, LW RRA AOR, LRA BE ERAS RREMAE PL ALARA SI PAARMRES OEE AERR EME MLR BIH Lee— BA AY Le TRAE AA, HAM, ALARA Bi LMHO ERAS, LGW RRE AR LRA SE Leo BR RECA WE BRE BR LAE BG LGR BRAY, LG TREAT, ONL RE LeRmER AM, LWW ARYA BAL, LE LMR OBAAY, Li TRAE TET HE Lg = BA LB EAAY AK EBA KE, Le TREE AR TER HL ARE Sp RRPBRE BR GLARE SI RRA AR ML ARE GG LAL Be LHe 2 A FOE, EL LO Lee kA Lem ER Lee EA AE LM HARE HRA MOR KE, LB TRAE EE KE, LG TRL ER LR SeF ik REFRAGRER RAM OOM, ZS RES AREER ZS SEAS EWE AE REE ES EA BET ARI RR BH ASKER HP RRAW AA DO BT RRR, PEMRRARER PAR BIRR — RPE ROR RAT AEE RR) BO RAE LE RFRRARANHR. HL EARTREARRRRRA BLL EHPLEA SHR LH HALAA SHARES, UHI BA KFPLETRRSHAAG ECAR AAR HRAD EHR SY REFRAMSS MS TKALRERE. AFRESH ZRAGHARLASHS PWR RR BE REAR CH RARENE He REN LANRRERMEEA SHER APEAREHERAPURHE. HAAR, FEAERSHE H ERERADABARS HAH BAR Ao ROR OR, AH FRAP EH SRAE, WHS PERRET RS RAT ARRAY BE LAPROLAR TEMES MBER EAMANEKABOTSE HF, AGBSNA-AR AAKRA-APHRA AP HY WBS BM ER FORRES KAO EE BSAA PHAR UREW EE RREES LH#ERMASS ATR FZERARLHLAAREPSH ER, ERE ABHHREHE SABAH REAR RRS A RBS 5~6H, ERZW WL-+ATATHSRERY SHAMS HH BEER So HEGUHR AP HRABPDRAUKRRMENAR AAR E RA ES RRR DARA RAR WB BR BOHM it RE PHTR ARLFAT-REXLAGRRRARE. KB BA BABE OR RHE BY AL, eT A RM fo VAP BAR A PRRHAE RE 9 AGS EB EH RET EK RA RS BRAKE SEOSS HARB OZEAR MA RAAY LREAAR RERASE PARAMS PTA ARPA, AS Siti2 RR ERB BA AMTRA NTS ODES TARA RE, HRA RH ABPPESS T PABRLAYAWARERA (HA -MEBAAS BASS): Janeway CA, Travers P, Walport M and Capra JD. Immunobiology, The Immune System in Health and Disease, 4" ed, Current Biol Publ, New York, 1999. Abbas AK, Lichtman AH and Pober JS: Cellular and Molecular Immunology, 2" ed, WB Saunders, Philadelphia, 1997. Roitt IM. Essential Immunology, 9" ed, Blackwell Sci, Boston, 1997. Kuby J. Immunology, 3" ed, Freeman, New York, 1997. Klein J and Horejsi V. Immunology, 2" ed, Blackwell Sci, Oxford, 1997. RBRAAB MAM eS MAN Ra SRL ATER ARAMA PR FBR, HRERR-H FERAL. RULBRS ARAHBARERR eee! IER 2000 4F 4 A#-— ee SR F (immunology ) AE FAH HLA GLI BL Fil AU HE BAR BLED Be BR GER BE UES AIAL DH HE. HEE EEN, KK (immune) 43K RAE H 5 % BL (immunity) Ht BE AB Ho RAG RERREMARS ERIS FPR BIA BIR. MTR BB HRT ACURA ME ERE OW TE TAR, TTT REE EBL tp JE Bh ERICA BHR “AHF AB AAE B” ( self-nonself discrimination) , 432% T — FTO BAA RARE RL BLE, SW KAREN OT RA A REE RS BI 200 2 SE Ri, SEE BE A: Edward Jenner SA 4 481 Hil 418 BE A FF BY TA AEA RT EE 1798 FRAC Ko HG ERR HEAT PED EAP RST TERS EAT. ORR ATLA MA 1870 4F AOPRA RS ADIEU TEAR ERAT EA HK AER, 23 400 AEF RUE HF SAE ABET T ADS BERD ALIELS 278 A, AR BE HE TG EY BE Ho WR BARE 180 FN GREAT 1976 EER BB RUE AFP BAR SEN WTA SBF 1980 FELASA RR. BULIE REE BUF BPE Hi AE AEA OO SA, FE RE EIB RS EA IR HEAPS T BIE LA SRE” , SBE — EA BEE — FRARKFR RMR FES FTE Me BR AE 1B] (1567 ~ 1572), 4 AR FR Be” BB REE A a Boo MAUI ACRE a A RI SN AP HEP A A A) RO BAF ADEA RAL CA TEE ) i BB HE Re, SB Se ERR A 1-1 AK BOE CRBC E)— BF CHLOE) PA AE. BOR EA ak 4% (variolation) Xt HVA RAE TSP Re, BOD FEA EE EFT AL BEATE BEE Ro R—PRA ALE RP HR A BE, F172 EEE HA RA Montagu “7 A BX SM SEAT HES™ (A Be TS HO BB EK ALAR VA AE HAE BEL AH BE HE FF SE, ORS ERE “RIM IE FE, BOT RFE” BE : OME A), 1741) 0 ROP MT BY EAR AEE AT RAPD HEAT 5397 96 , RA TTT AC SALEM FR Se See — Be a PE Oo TTR HE + RAEI AGRE — ARS ALT LI 0A J AE I a A. EAE UA AR D OOM A ROR HEA I PA A A AR LA He LR — HS EE2 EF fA) BB SRL EE Dy ee A aL HOCH AR a WHEL. Re RA aa Be HE a THE JS Jenner OF 4-484 Pasteur DFR SOM HERE To HE APE, Jenmer EH tH AF EEA Z RIE — 1A Mi ALAR ACHE 8 BE RAL AST EE ID SLA SL BALE ABE BEB LO 0 9 DO 9 EC SAA SRE BEAL HRA), RAE AE PE BRL TE a BA AIR AE (ESE R ETE b” OH A AR IEE FEB | A SAR BA A Or A ARS BU ASE EDUII ME) «LAR, ACRE TEA. TB RL D1 ECE” AL HP LA, Sa ATTA E SCAR. 18 tN FEY, LALA Volare (1694 ~ 1778) A AT a AE He) HB ARLE Ct A ACA BL) ROT BL 100 AF BB 1-1 ACRE) TAN HT A HE) BIR RA FAVA ARSE AT AREA ADI. aa EAL SEY — PBR TE A fk Bo ARRIETA ERT TD AEA” Voltare 5E/G 12 4F , Jenner 38:14 30 32H A AGA Dy SREP LAT i, OIE AR A BD fH ARATE A SAR AE CSE YEAR) TE SE fh) — PHB LRN UN AH 16 HELA HA = RREBARE SEO 20 WEF, SEAR Ae OR Sr, Be RAR EA AM DAE Wy NGL FEAL BS, HU SME BW A RP LH TR I SR Ze 1-1 PAT 30 4K (1970 ~ 1999) HAF Nobel BE AE MAE HH Se BEA ARS FLL HH AERA A A EIN PRT EL EK ATT 8 IE 1 Ag ICH BEG MAC MoT SLES CE ALF AE 9 BRR, Se Be — TL A MR TK Ar. a il BAR 7k BG = AK eae. " RL-1 W201 70 FRR Nobd EFEBERNRTER = Eee ERD 1972 Porter RR, Edelman GM ecb oN Heese 1977 Yalow RR BAH eR 1980 Snell S, Dausset J, Benacoeraf B ERR STN 1984 Milstein C, Kahler GE ASEM 198% Jeme NK RSE IE 1987 Tonegawa S Scie a8 ALE 1991 Thomas ED, Murray J ieee 1996 __Daberty PC, Zinkernagel RM TAR See MIC SE= SE Re 3 PAL EIAG A TBE 1804 FF TEA LEH HY 32 IN hh 20 HESS 40 EAE. HEAR ERE PEEP ALL RA HBS ATES AR TPES 0 SH HED 3 BE HE (1903 ~ 1992) AA TUBER (1903 ~ 1988). AEA ATT ANI Ate — HE Sa EAE BE APT , BB ee yh BBE FERS OT BRATS iLiad AS, ARE BUI TE DA AY RAS ASS A 21 HH 2 EH PEAR. BOF TUR REM RR — RRMA FE CCDL LA 2: PA Se AA SBE YC AD BOR immunogen) . HA $22 EAT Lk DERE TE RAEN , SBR RAE immunogenicity) ME AIS 8 1 AE Py (He A See DURE AR) AE A 1 Od EPR HY 48K (antigen) HLS BAL PRG Se HE NE PO SB HE yd RE (antigenicity) HAF JA Sea DA DR Hd a A HB PR eb — PL ALK, BOP Se AS DE AE DHE OO EAT AR (hapten) ABATE ETT ARE RAE A TT DAT VAAN Ae AIA AB HE RR SRE ERE ME ASB IRIEIN A Bh 5 A Ib AAR SS 5 54 A Se. = REKAREMAR LER Sei 2 eB A Se EN A SD A HD, BH DT $Y F CPU) SCTE» TU DLRUEA ULAR SE BW 22 BAY RE INAS, ZB BEE PRIA ARH 5 ATT Se BE HE AB Do Ie, tA BE ee RAK Cy RRA BRE TR 1. (HOHE) ROD), Se RA A BE HE, Ri, ASA SPRGHEVUKAE K&B (germ line) AVFSAN7" 9)» (LSC A: , SRE GEE COME ESB SBE HS ATH AE A HD BE RE RMR BE SS SR AE AEAPTAE IE 3 a LYE A RE HB OB, See A ATO PERAK LAR Ae HL EP a A ih 2 EBL EE BINA HED BUM LIT FE 5 FARO RENE BAH REAM EARN. SROKA RSA Dh, HCO AHR I a, SBE RR ML EL (BSA) BEA EAE PRB FR SBE RYE AL S| A SEA Bh WO OR A WU FS See DLE , See YE A SB LAE BSA A AA FZ ALE ACRES TSE MM EZ NE GR, RZ NE A BORE BE BSA HE Dy BURSA RAHA, EJECT ABR et HE AE A BE OR SPB) BACAR, REAR MR RUE. RAM LI TOR ee ES ee REBT HEA 2] AR AS Se Ek, FCA at (i A DF HR) VLE 100 000 noes — ARB, OYE AME 5.000 ~ 1 000(5 ~ 10 KD), S285 HEA EE.4 KE 3. HERA BE: AAT AB HAY HIE He BH , ch HL — SR ES A AIRE, RGD FRA RB KI ASP RE, 19 RTE 0 FR oe A Pr ER (2 Pak 2 TL ERI PINT LPR ee EER RIA RERTE. AR MIA MRSA HHRABG WGA MAGA, HERE TAA. MAAR AO OR A DF REL E 30 000 ~ 40 000(30 ~ 40 kD) 7A REA HE; HA Bs AR, SP FG 10 000 ~ 20 000( 10 ~ 20 kD) 527 FLAS Hm A Be 23 Ba A 3 PS SEA, SF HBL ARG 2 4000 BN rs Se BE Dk to HRAW HF RENE DRE RERIR HRMORAN, AR-ALBA BYE a te He BOT SPRAY FE 4. ARTE. SA ROME | T ANA Sl ee BD, A A a RS F® (APC) DACA a MHC 9 FH EAE BT SHED Sh SY BS TT UR FER ARI T AS TE TAD FARES TRIN Pe BOR AL JST F 2 SBE SR LAT SG Ph OB SER EL, WT DD RE I, SEH: ne ae ee eae iY 4a BF BY SBE DR 5 HAL, FT Re, (]) REARMEHA FOR 1. REALE TY, ARTA] MHC #5 Si ty 5B By yt DA RP A OS J BAF HLL ADL HERE SY KR ERA (Ir gene) (HAHAH Benaceral FAM ER 1980 4F Nobel BR A: HARM ) IEMA Ue REL iy BEE MHC SbF. SEH T 2 AY Be EGR REE, TT AS Td 9 EA aS TO) MIC. i ME BS, J SO BS ST ‘TAS SEE, AE A PE 2. SARAH E . GCDB GIG SS, LG A PE TG 4% (immune tolerance) » TESA AY 5 SL tA FA — LE — UC HEE NRE, A BT ATT EERE SE, Sh TUR A RE EBS eRe AS aE FORA SSA EP EN HEA ME; Be EY SU FEA, AE BEE PR ES PEA I BE AH AU, a Se 3. (EFA; AeA (adjuvent) 2 —AW AT 5 HL RIES HF SE RET REN OA ET ARRAS Sy Ht) Se BEE, TT BY PAE HH BL A OS BE JS RAY SE AE EH BEDR TERS , RAL RA Ms BEA, TFET TR IPR ESA PE PO EAL ABH ADB FU SRT HE «EAT 5 SS Se 2 IT EY WAS EAE PAE (Oe Ea MRR) BAD CARE SE “Ty PES = TB SABGR BUAR Pel aR Se SES HAL HOE BSC He UL SEPA RE PS FT BRA FEB PAEHU IBS) , AK WY AAT (epitope) Be 4k MR AR RM (antigenic determinant). A ii HALRB T HR BF EDT RB TER , HA BEM HE TRA ADU FE 0 POLI, GERRY FEFEESEL MY Be AL TD AR SE PLE EE TLD Fo TB AUGER ADA RIBAS LB 5K (FE 1 2) 9 TABULA BS OF — BF EAA SP DPR AK GLURNY T Sa AEA BRE. aSe mR a 5 Ri-2 TB MMA RIE B # i T # if AUCH fe FO TUR URUIK-MHC-TCR =i PTS Aa W s Jf MHC 5}-F 68) Heat FRB wha, RR MHC 53-F iB 3 oh RE . DURA E E RGR Sem ERY? beet, §4 vo RAE ADELE, RKE TSH; MRK A dm Tae He Bk Be Be MHC Blah CARAT Hee TI REL (=) Ba em (1) B HHUA ALATA A Ea SUR FRE A A Eo TL SR AR ETB ALA TEAR BS AE TBR 9 2 tH BE (2) BRE RL DEAS B 2 Hele 0 eo eT eH EH, FT BME AE IDURD TF (3) BALA th ERMA EMH REO RI . SHRED THR Se AORUHE DY BLA TR , ATT AA HE eH He ok aE conformational determinant). 3% ERY BE HE ASL ROD Ff 3) AE BE PAL I, RE UAB AR BO EF. SBD SAR Hi Se Be ir HF OI — AE, WH at — TI, Be CE, (4) BIR HT TRO AER SAT tk, RF eA REBAR USM ENA LARS. KMRAMEERU NAS RMA LS Foe PARR ERMA A RABE. (5) ROSE As HY FE BU He PH A) B OH A, Se a 463% (immunodominant) 44-6 (EFA o (=) TAREE ARE TE BD TAA A A PE OH) ARI TT EA HH ee MHC 4} FE A TRH Be RAZ, TMT LAY T ALAA, BOGAN LILY ERE, th AR A BE TARAS PAT BES T AAG AeA AT GAT BB ST LATE Re BR APC AL SAU AL RS i RB a LO FS HE) BGR TH EL J FEL MURA DUR FEB RIO IEA RA wT SOBA EEE. SOR HEHE IE: (1) Sea mh Pe a, 5 Ha TB = 7 2B) MC WAS TCR IAB GB) ARAMA S BRT RRMA, TAMERS EAR TZ A. BE, BAL ARAMA TS HR Ae FF bh (4) PRED DALAT 0 HG ee Be ic HAS Rs , WLBT AB A A 3 HB PLANE MAC FF LASS F , AR BOMB Ee MA fe LB A A) MHC 9 ALE A aS) MIC 5 3S Be A HS aR Ve) — SHLD See BB Hs 04 3 FFsaan Pe sare Po B12 MHC 4} 58 5 Dake a ww} TCR BUH SUR AHA (—) RBRMES SRR 1, SEACH: FLA BAEC 5 AL A Se FE CI, SK Z 5 BAR AE A Dk eI AR A SO AR BLE SB WE 5 BA i AT — tu. 2. EGU: AT RM ETRD REE ERLAR TA EE 5 I, _ EERIE Be, REP Ta) Be EE IR A, B A Ae CAT He (3 HS BL FE AA A (=) RE BAMF EARS ER TOMS SHED 1. IORI: BS TDA, 3 IEE a 5 HL UE LB A RL A 2. SER RTUR: AA ThAg, ERRSRARERESR MNRAS, WSR HR BUR Hh PAE eM EAH FRAT EE EOL dE Le TE (2) RETRAIN RRR ARMED 1. RAR: GERALD MER MAA EMT. Be RE SUR s EET RT AS BY BU Ee Re A EK ET S| AS, BEAD PE FUL EU 2 HE tH BY PE SD PAE, BRA o> 04K (human an- ti-mouse antibody, HAMA) Ai. 2. APSAER, IAN ABO AGT AAAS EDR, Fa BE | A HE FOEZAR (FRBORABtCE). 3. ASR: EXE BRARAM ARTREERE MS. WRT, Be RRTERASRE WRAL, KPWR-RANLRHKELWFERR EE BSR RTA. 4. PRSEPEDUIR, FFM AAR (heterophilic antigen) 48 7 Fl 9 FF SEA UR AA PRES A A RA Wo 9 ELD A BS SB PRR Sa DU) PE Le ER SP) RE EA ay WL SA SB To OE BRL, PERN AE ESE A REST A ED, PN IT PAE.H-e me i BH WEN S sea SAH A BOR IRE OS Be HEME HA LIC 3 TH TT WRT AS Glee Mal ee rea eM. HZ MAY WAP BPE 3 (polyclonal activator) , SU 35 Jz AT ib PUA i 2 HL 4 PORK, iC WO IRR FOUR, A CORA TB MSMR A Hee EN ERE IE PE VAESPL AT | BB UY Se Ae EMG See LAE UE BSE A ACOH. (-) RE (61 ETP HE AY TB SRR AE AE 2S yD AAR (mitogen BRA FPL LRA IEA RAR SY , HEH BY RR A (Nocti) AB — SR AAA EY RHORRAS EAA, BRKT — AAMAS AAS Sl RAT A RUA HL Be 3 PET 3 AL AAR A SN ER Ae ES SEH Con, ALPHA G5 T 408, PWM IE) ES 803% T A 97 B 20. 21-3 RERMHNS REMAN Res x OH x a eo DERA Con A Jack & AR Tae mse PHA RT mae Tee SH ie PWM SHR RR TBS ee es cat vee Bah sab” SAg crt BER Tae, "AIRE AAS, A BEN AH TSR — 9 A (=) mate 2 EDA OE 2 AE $A Lipopolysaccharide, LPS) 8184 A #63. BLE He, LPS 1 te — HS AA — Ry TLR SER A Ae AE NF-xB Al AP-1, 3/2 RAPER AMMO, JED ARS AR ML (2) Bi $8.32 74 (superantigen, SAg) JE 5 — 28H HY TB A SEREABLE A, WOR AOR TAL SC, SE © A = A, A A HARB A (stephylococeal enterotoxin, SE) #84) A 21 (SEA) B (SEB), DI Ba MAILER A EME CTSST-1).. BOL WSh FSW TOR B EES V RAPES BMAD APC THEM HLA I SFA BR SE EB" MHC-SAg-TOR” = Elk. fle MC HR STOR” AF, ed aaa 2% = 20% ) IE: 5 TAR Ba 5 HE AE SE AG HT FB 5 SURI EB MR Sh SR, BL oh a AR SBE NAS AOE TALE. Ta Sb RARE TRIE B SOHAL AY ACU, VA Be OAT AL UE BRE, GREBLAEPD CER PARRU. {8 : SREY SSA RAR BE PSE LMA EAS VE Bis 1 — FRRRMRAERR KAR KM (innate immunity) OLA AEH HR BP A HE AL AEP HE SHB BSH IE SEE TE FATE A ATAPI DUR; EAD, HB. SARE TE EE RRA, 3K (adaptive/acquired immunity) , 4 tH A J 3h $5 DC I AR fk es EF A BY — HR HB BIT Ae, SEER EEE PERE BE 1-4 TARE AAR HE SE EB Ri-4 RRKKMRGELSAT HEM LR Peet a eshte ait ite 5H eset FRM SAT SETAE a % esa NK aa HE Me RRR URE +m a ee + ARERR HE = RRR A Mee FAR SEBEL PR BEL LL RR A BR BR AERA I A Bi IL HD AL, PRAT AY ‘BEV i, AE] — AREA La BLP 300 Sh, gk PS A A EE ‘UE RE HE 1-5) 0 (-) BARR FEED LE IB DEAR A 13 3 BP BE LA RB SS — I PR SEE BE RARER. RA-S MKOGMERRAR xo a fd SAUER | BRK BEAU ODA BR ROPES (pH 3 ~ 5) BAL ACE AE ERR TEN RUA RIE Soh NA RR eT RE SESE HE RL AR I RA I 4G pH ARATE A RE APES RHE UE G LI 5 FR A ARE A Ae PASE AREA SDF SA A AC A emcee tim AOR eae 58 RL ee A Hs a BRERA. REINA ETE IN AK A. FL a a A a EPA Re ATER BC PL FUER AE BE ATT R— AP pH 9 3 ~ 5 ROAR TRIBE, HO CARS OE HE KK STS He TL SRE A PO A Ae AB DS EH RB TARE ATA ES ABC, SO ERE A RSD, — FEE HI ETT BEA A RUFF AEA Tt I HE ABE Be AD, Sk HT FE A HH Fab, F MPI A iM 9 ARE FE, ATR OO HE BU AE BOTE amene me 9 Ay BPS TB RLF NYS DAS TE BA SH TG BL (=) 28a TEE (AOU 22 2h) RA: Ke a EA. SRT AREA A RAD. SHORTER RS SAR HY OT. EA RT Db — BE 2 A SE HL BE RELY FRR SA HE A-KESREGAHRS MPRA RIM, AKABHER BRE RBINT Io (2) SRR FRSA HE A Sb eR PTE Ks DT A 1. HOE: ME (endocytosis) HHUA AH SURE HAD FB BRA 0 OTK LA NAA ( pinocytosis) MAE bt SOY HOE 1-3). WR A HEAD Ts a PEMTEA SRA FS 0) 0 AIG, HEAT AK DF 09 ROR Ly HH EW TT EA, A 1 (endo- some) oA FRY RTE A ME A SPF SS YF AE a Des AL FG He TAF AT BEE AC SD FB A PAF GR ESE PR BE 2E BB AK (lysosome ) Hk A HRY UC RTE BA FETA BB OS BB AH 7k PP GEA PAD FR KK TALL FARM PR ST 1-3 SURREY FA iE (Ae) A a 2. BME, BH (phagocytosis) 44250 RUE A URLS i tn 7 9 DL 5 A A Ae — ARR SAL PO BRU ANH HCAS AN HEAL 10 ~ 20 4850 POM] ALG 5G PE A ERE AC RHE RAT REA PLD CS ETERS, HC RI ATL (05) Rak MT Be RE BED ES BL RE UR AAS A BY A ety AN HO FG 5 APA EMG Ce, FP A I rN. ER DF 9 — RL, EAE Rsk A (inflammation). RSE LAY PL AE NL IAI EAT CAR TA a A EF10 BR RA PEL 4 eB , eae AeA at , i ET SR ESM, SP Te A , BL eA, AR ALE AG ALF AAR SSH PLE EC wy EE SE HG AR , TH BG EA A SRE, 1 SO A a 2 RE a 2 a CE SATE) BEB BES HD FSB PR EA, ce HS CIA 0 ACL AR ES TE, NEAL A BRB AL BRS Fa CHL DCP RT HT TEA 98 SP AS BI PRBS 1 AT HA TE AH, 4 aE BR LAO Yk HAT RR a EP (A) Sa A Sa a, TH Tm; (BT aH SA A A a AAT EAR (C) ALLAH SERRE SY SEE SSRN AF St AS , ALT CBRNE AK AEE ES (fibrin) 4 SSAA Ep HRSA A , BEL EB A, ER EA, SS ER SE Aa HL BS AE EM = MRRMRRE 4ME (complement) J2— #4 fl 3 BE A WE, 445 20 ARAB, MARLEE ATG 56°C LE 30min ABR SETHE MAE OME PATE PRI DER IF ee TT Ao APRA AMADA PERI DRI TF HE, SPE PEALE GE Se Be BH i AH EDD PE AAT EPE RSA BALA PD Hr BRC LL) ELE AS MA ABU Hr BRS “EIA RAR A A RO Be Ha SA Js 2 I Is PAT 2 HLS TT, SP SPS TE BL (=) ARBRE UR RM BRC WSL A 9 A BRS SB I TA (cascade). SPAT BT ERS} 3 BR 2 HMA 3 A: A Jes HH A AE, FE} BRIE C3. 42468 (C3 conver- tase) HITE ALTE AE.sume, | Clg Cie cle a wat | C4c2 (ote) C20.05e |p Sabi ~ A Cota) MBL 44 MBL, MASP-1 or Gan) ame >| Mase2 | >| cose cab arn 7 apm + wm _, | 3.BF SARAH RY RRR ai DEF C5b,C6,C7,C8,C9|—> HERES FR 1-5 #M REY = ae ER EB MBL: #1 SBSH mannose) 23:38 HC MASP; HTB RSE WES RCA IG 24 I SEN SUED Bk = AEM C3 PCAC (FA 1-5). 1, BEARS MAT BLP 2 BEE IgM Bil Te) ta DR BR eT I FB HEGRE Bh, TMK Clq SbF HAE TI Bk — AE, Clq AM Clr\Cls ETA AR CLL SD AAW Clq HOE HTT ROR WOE, Cls BEE Hie, SHE EB ANALY SPANIEL. CA Sb 8 Cha Cb; C2 APA IR Ca ff a 3 Rs Be hr TP C3 canab(IL HS C4b2a). 2. MBL i@42; MBL 4904) 8 35 98 43 GR SEK ( mannose-binding lectin). MBL #] LA #1 PRPS YH BR 2 8 J ES HE BH 24 EA ( MASP) Se 2 C4 ACO, tHe A MAY Cabo Hy C3 FEAL 3. RE, ERB EAN C3 PEACE K A C3 THB C3a Al C3. VUE AL RHE C3b ALS BFA, RST Be ED BAF AY BARA BES Ba Ail Bb, 28) #8 C3b #1 Bb FAQS A), iy BAC Ae AY C3 HEAERE C3bBbo SR HCW, i C3 EAST IRON C3 PF A EL He AS FL,APS29 C4b2b I C3bBb. XH, C3b BEAL C3 AEMESHAR C3 Za BRAND, LE C3 BBS SL RIS Wt CT tT eA FE CK BL SBIR ANAT CSE BATT T BR MD TT AN RBS TH BEAUTY BOE RAE. (LIE ITAG BIER TUR IT RAR SME I REO SVR Geb AACE RR LE LI AD eA IE (=) APR SR Ab am SH AE Ae AMR ot 1. C4\C3\C5 4h PAE HY ah HF BE Ca, C3a il CSa HE — Fk FH (peptide mediator) 5 SB A (Ae 1 ~ 6) AEH TS FL, R1-6 IMERAMA MADRE ae a woe te Buna tE ERM aR AME tik Rea ease Ces Ba Ses ma Bk Ca, Cu (Sb,C5 CRI, CR2,CR3 Ca €7,08,09 ___CRA,CigR Ab, Cab IMR Clq MBL12 a : KRY (2) 3 MLR BR AMAZE, OW 1.2 mg/g AP C3. ET 3 10004 C3 SF HHA ACA C3b Cb SEAR ICRI HH BREE (thioester bond) LSE Gt FERIA SE SIUM, AML Cob HLA ARTES ATT AMADA AY — PEAR JE Cab “A HEC BURVRL Be GC RAC 2 3 — a TAA 3b SS 5 FRM BD REE AS SP ERA Cb SPA UR RT ‘BUND. AMIN —9) eA a8 AE AX opsonization) » ERE IS Y FLAY AMAR (Cb, 3 {048 C4b) FE NIBACopsonin). 21-6 AAMT T 5 RARER, Hob 1 USEHR (CRI) TERS C3b Al C4b, ER RUF BOM AS KA (3) C3 SEAGBSE ARP AE A C3b, A TREE JES C4 C2 AS C4b2b SERIA C5 HE AGRE (ICH LIE CALE). C5 FEAL BRAN SH ENE C5 SEARLAR C5a A 5b. Ca BEA WAR HUH SE BD, WT DUAT Cha, Ca 8 4p See i SE OL HT 5b, SUSBENLE > C6, TELA ILI BE NEA REAWER ABUSE C7 C89, 3K 5 ARAMA A te — #255 C567, IML E 12 ~ 15 7S CO APF, PEAS IR AR Be TE AL 4 (membrane- attack complex, MAC). S30—A> AR BR LEILA oF ARH, VEEN 1 om, PU “ACU ESL ROAR EL AAPA GRA TAH BA 9 a KP FHLB A S98 EF EL ACA SPIE ACL RRS AES MO. RI AEALIRyolysis) MSC IBCSE 2 a. 8 i Ee hy ABE 204M R484 $0984.18 complement-dependent cytotoxicity, CDC). PAT SEE 9 0 #6 fe Fa ae SULT RAS TESA BE TRS FEE I SE BB TERE LEER. PERE A A BS SUR UR ae DR ARIS BAR) — EB RTM AS BEST EERE REE A TE RS BE HE BEL, RAMERR AE ERE ETP Tate. Re FER BE BE BA 3 id UH A, EE HRT RE EM — FHELBLRS (-) EER LL FRE, UR AS mt A HA 2 SK BA A AH fl FR PT Se EY Sete. 2. SRE: 25S He ALE RL A ORL Ud te LARUE RHE AP UA Aa AE SR LAA H.-R EAE I EAS SEE AS AE 3. [aia FEU FFU EY, oh SE 1-4 DARA RHAM ERE ER» (=) BERARHRABE 1, PHBE Se EA RG SE «RAL OT EE SF SS A SES RM ‘BE Hed Se BEE TA HAL PSEA) SBE LAS Dy oHae mt 13 BEF GE BE FES SBE A HL Se EIT AR RR RA A BEE EP pg DBA SE FA BT WBE RE ATR a Heb A (MER) OP A He Js RY EP DEC, ee HR eT A AD, WR PLE A Sa 2 (2 HH) 5 RPE SR A FY GP RC), Js HD EF BE 1 7 AERP T eRe ERT AS FFL AS DRA AE BA I 0 R1-7 RAKAUNSHAMKAARARGNLAM SORA RR PMR IRAE * wa Pie Sh +e + ‘HF SEAR BH (Sireptococcus preumonae ) ra a, ee a LB) ‘BEEGPLH ( Clostridium tetani) a, i EG. (Trypanosoma brucei) Bee PRE - 44+ DIL IH (Mycobacterium laprae) WES, (a, es) LEGAL SBIR, (Leishmania donovani) Ae SBHEE IER ( Plasmodium falciparum) ee RA) ++ 44+ RAGA (Variola virus) RM. MATE (Influenza virus) es KATE (Vasicella virus) kat wx 44+ * S818 (Ascaris) Sa {HLL (Schistosome) RS PRET HE PRS RE ERP AE SCR EAE BAO AG LO PR Oe “TUG, TS a I ZS PERE AR, ERAN SOME, RE (A SA AS A hE i AR eA SASL ay ee PD Ia ETE AL MR BY RE PS A SB 5 AE BUR), BPE TSU LA I 7 A TAAL CTL) 0 2. DAMEN: BERRA —TUR, BAER KB JERR, RUS EAR 5 — RE A BE (BL 1-6) 0 RRR BE (En Sue FA) A He eC ADT EF RM) ABE OR UP ET I at, FD 2rd A SLATS AB PE, CERT Sc 00 HUI, AEA PUI (HR 1 6A DASRI2R FRAT; A 1 - OB LAU BEAR ARTO | AOA. RR UMS SATE. WME SITE eRe PRUE ETE MIZE, RAMU AEA HBA, RBI LRAT REE HBR PA PD KBE A a IEE LEE HL PRAVEEN RCA I LARS J — i BB AREEE ORE. ~ 3. SSM RA. SPREE REL EEE OLA MP RRS AYA SHE MLAS DEKE WAR, TEI A aS SLA BLO PTT A: BSE. AA EL DRA EE UBS GA i A A BI Ap Refs AB ELC OGL Pe RR AP TEE I PR ARH 0 BSE, RT CLL DML T BNR TAT PSEA TT TES LR EEF AE ERE TAA AHO TEM.14 KE AE 2 4 6 8 10 n (ay yox nem Selma ZX HRB 2 RMON Ek () P16 PRESB (A) ALA HR SAB) PTA 4. PHEREMEH STA: (12) Ba; TB AiR E52 He TCR Hl BCR ABR (2) tits, TERT URE ea AL Wf Eo (3) Aesict; AESALMASD F AI ARAN eB TLR RE = TA AER FE = FRERRRSHS AE TTB LA SE HRCA DGC A BE AS AN TS a A SE} MSR. SE RE TRA EEE TE ARH HEIL) RR A (SPM) BE RA. (—) S5#FARAR ERR MRS PEAR 1, BAHU (BCR) ARS: ARR A (Ig) MARS. ERLE BBS iH AR GB De ACB SP AB EE PRL EH A FH IE Did AE (SLB =H). SPREE ASAE Ma 88 AR) A223 78 FA BCR 4) B Se BE FRAMNTAD TAF._ Boe me ets 2. TALMAURSRIR CCR) SIA ROR, APPLES Me MRS ALE BURP He. REE BE PRL AEP OR (RE) PN FRI ANTAL TCR TATE AC 3, ERSTE A IR(MHC), SPEEA AMA RLY FRE (polygene) Al 269 £14 & AS12 (polymorphism) , 4 bili FRADE, MHC & as eed — He Ae RAH PAE, RITE Be AS EA LR ER ACER UD PRET A HRP ATA SAE RAINES, FATA MHC SP AT De SEY BARA A (individuality) #906 FRGE © (=) FFEARBRS OW A SER EEE BE LEE, SEB T MAP TB BIR BLD FS EEE CRE BCR/TCR 2 BR 2 ) ALA IAL e PRO B EE N MHC SER BE). BE LA AEH UE SR RS, SR HOSEA AR, Fo AGHE (repertoire). TYRES AU MUA RL BCR/TCR AY SH AEA HIE ARATE EAE Te A SE ACHE RE A EE SLR (skewing) STE: BLA 5 ab, Des TE TWA HEHE See MLA ZEA — Wi WH MHC SAHRA THAN See BOD ROIS. BATT MHC AYRE FEE SEC A J HAS 9 CE Py (MEIC, 4) LD HIS 9) eA ESAT: T LDR AR, SE, MHC TA HE, LTT Aypit) MHC 4}-F TB a: i 2) — i AS I, ET PA Ta ee | BALD I LEI ARF HL 24 Sh BH A IE BE PE = S5KRARRVANNS FSRAELELS (—) BERR MDF HT AY EE 7 2 LAS 2 Ie HR fH professional APC) 7 T AAU KO AY SCRE Pike aE TREATED. HE LAE TA «BS A ED IAS. SOR WORE Aa BS Be MHC 5} Bb OI SF IY VA Je WR HE 22 2S (constitutive expression) , th LE FERIA (inducible). AAs Hh HH AF ML ATM A. ASE BAN HL tS EE AL eR ee Ta) , ER 0 a SAE, YAR A TA 2 i Pf eS MHC FA 2 APC AIR Ai MSC A. naive) T 4 fd 6 TERME BR RN, (=) BFRRARHAMDAF A TARLARD ERASER LES RAN HA ER AE My 7 My (HO LPS) SRE AF SR a FA 2 FA 2A HAF 0 WL-1 TL-4 12, FRE UH? EET AH HY oh A HEP 4b (THO fA) Th 4b HE )RERTE SHEE 5 5b FOR / A UO HL SP TL, Be We LSB AY TL-10 A] F Th2 AVS TAH Hal Th Yt BE EAE IRE EBL, — PSE NK AT SO PS YT TE NK1.1* TMT ACHES} OB IL-4, Ii JERE V9 VO2 TCR AY yd T AHH TEBE P IFN-y, BAS SG Th2 Al Thi 9446. Thi Al Tho AH LA A Sh SA See A PR ee, BS WRN RAN. Ee MO RTT IE. (2) FERRE MMPAFTRERER MY ROSSER 4 AER ES 2 UE A 09 HT Bg A SR EH NK SE AB16 LRRD BY Fe S24 BD FeyRI(CD64) #1 FeyRIM( CD16) , 345 34k HRB dn RSP A oo FEE FA ( antibody- dependent cell-mediated cytotocixity, ADCC) . Ak Wht Jia 2 4 Hel 4 2 HEAD ‘HY 3B TL BAY A5 AN AL 2 A HH, Se * (US) aMR Ae BF oe a AMA ODT B14 FSP GDR NEB PF Be IESE SH EIA, BSG EE SBE TF HE FS RU SEA)? SR (homing) . HUT EL HEB, AMAT HL A IR EE AE PE PE Fi, SDL IROL DR BRAIN Ah 9 et (CDC) HEIL 9 SBE OAD FS 9 SL BF, VA 2 09 J SE SE 8 PE DB SH A FER TE RBCS A AER Dh fe (A TNE PRE AG). A FR AE TB 2 HBF YP AGA DB EP Pt PRAY ZK] HEAR (class switch) PE BE EA SAE RBIL SS BT LAB AH, BEAT KAR GEA ALD BSE A. AR eH A POC PE GE WME FIR BEAN AR IE Se REAL TE (1) SBE BEAD BT SP BOE Sa TA A PE RE MS ‘UR HE HY BI I BB AE A OT A RT GARE WETE Go MED SH A oe ME PEE TERBEE RIE PH — FURS TA Be nse ee (-) BHRARE PATER FAA EBS BG HES HE ME A RL SE RE a A BPE th SRA BARD FORA EAA RAD RAZ TM RAIA EE AE FETE SURES R— TPE EEDA OL, ERB RIE. SERS RL FTL BER A A ACRE TG HE” a A EAS DD A A EE WHAT RSP BT MIR AT. MBCA TRE A TRE AR, ECB FEN BE RN TAD FH ADRES ZANE Bee” He, ER HEE FE RE BPE J 20 HEE AE a UR i By A FS — 5 BA HL ZS EBD TES aR, JA: Oo GE FL 2k SA I BB) — HS J THARARAOT A, KMUEAB ATE EMM. RRA SWZ AM eR FRB FTE. ROBE TERE DLA BZ BM MEDAL — LRN A DAB AT PE BAPE, PERMA F EAT A KES EDLAASD F (BCR 3} F ) AA) METER A) MEAS A iS AAS SAS A TR AR A FEAR, HS AS PE BE BENE HI. ‘Oe BH TE aH A TTL AY HE ALE RE AY BURAK , RTA AGE ATE RAUF A BE ESD BD BEE AT “RE” BULA YF, — BSE — BE BE Be AO HT ACE SPP REA PTT AERA PE AE Se BE He AD TCAZ HE a A AL (=) SURAT BCR HY BE Rae PRAY EL TE WAM AAP BE A PE SAAR FAS ET — Bt 7B-e Rt 17 RETA BEA VERE D3 UH Se DCA OR TAT DURE PK BCR HSB. CEA Fk FOE RFRA APE BRIE EMEA AAS, TSI BCR GOES ES RTT ARSE A SR ER RE SEES RE Ea, Cea a Se BOR 259 BO FOAL IR A A EA aE A ALR Bo A BEG SOEUR SEH FIMO STR. ROBULDE, TERRE PRUE BA SEA EET, BUM ALY SBEFR McFarlune Bumet F 20 22 50 AF (CSE RETA ARE LAA (EI — 7), © ZIIM—Y OOQ2C® sme OOO22 soem arn | | | aan CEO ananencians SE Ag a IIS 0 Oo 0 O 0 abuasuansn AS BAB a a a a “a IAA FA L~ 7 SERB SERRAE BS (2) Bumet 4H HRREFRER (1) RES SE A EB BS (2). Sb RUA BG AM Ha A 5 BH A BAT EA AB OR WURUE HF RAE SETH (3) BY 2 BRT 5-H I SA PE Aa IT C4) EAE HE) SF APO AR 2 A I RA wR HE. = RRS (-) RERBPRERD AUEREY, SRR APR MAR, HAR SAD F RS, TE BCR. Eoin ase18 $e We PEEP LSAT AEF TCR BT AA ARO DGC EE A tH TA FORE PEE DE. TRIAL AE PRA NR A TE REE Ae — A fl, RA BCR Ti Bi JAE TCR, JB TOR SE BIS EEE RST A PRD De PA DESY PR A HR SAS FED EMG LOAM, ART REAR EM, RT METAR), BRET RAR A RUS ENTE RHRA) VRE MAHER REE KR 0 PEARL, FEE RE PEE BEAR WE AR EF ER EFS AE Se EA I tem. (=) REREPRET HMR TSAR EARS HERR 1. PRESERVES AUARA , HTEL BE Dk, Be HAUL JE 2H eR 9 a BEAL TEMA HA TT FE Me SO BARR CS ee AF BH, TBE AY ERE SREB TT EE SE WY KE ALE (clonal response) AR 1 FF HE ML Si Lia, ARES LSE RE 3 SR, DA BCT 3 US RE PARED, SUC BUSS ROMER T UC Oa BSA, 388 92 aD] — JH, Sd — FR A BR YR BEA ho ARPES UCI EA I AO aR 2, HOME TDR SS SPESE , SOME ME PRP RY UCHR BS SP AT a Bei HE(clonal deletion) EU H AFHLSE ZEA, RAGAN IE BE AR AR 3 7 AB SE EMG, SLE AE SL LR Oe a HTT SS 3. TAHA ARM, DATAERO KDE RENEE, HPBRMTE FH, — JE BCR 254 SE Ba RB A) HR E ( hypermmutation ) Bl 4K 4 AW % IHR , IX — FAR HE Hy —7 BY LSS HOR BCR YS BEDI BASRA BCR SbF HAL SEAS PE HE ARR PAULA DLS SAE A: RD Da SEAT FA HE EE BO MRE PL WB) FS — ER PRE AMY Ae 7) (affinity). RAD SEREZA RA RRA EHS 9 A, AU RARE 2 oe, A PS A 2 WB, BRABUS” 3 FB AEE, (ELS EF (BRR HL ‘i, BCR) 24 BL DEF 2A AL EF DN AA eA te A SE HRT ASS TERE RL, FE A RATA PE BCR SLL ROY | AT BAR EDR ORDER OREN RAAT RERRTADT. BRAT R eat REREFRW BARR SAAR SER AGE TE A SUR LE PS oH eB BE Se RE AT TE A A ® (isotype) Hl Fl #P IB (allotype) , A) IGE S}Bi Er (11 HY ARAYA (idiotype) VA KAA MEA BARR (CDR) 245 #89 , JE BY 3 He he ERR A BS SP — a S&S AS A SP BAYA (EL 1- 8A). SSA AY Se EE HE Hs Se BERR AE A 3 F 0 5 B A AE nF BH TAG IB SRE RE SPF AE PORT BET THT SH BA Ra (3K SRY) SEE. FAL 1 — SB of Zeke 985 = 49K DAB ST Be AE FG RA DH, P= A Se RE ES A 2 8 es PT PLE RS